This Licensed Pharmaceutical Wholesale Business is a pioneering organization in the pharmaceutical industry, committed to enhancing the quality of life through innovative healthcare solutions. Established with a vision to address unmet medical needs, the company exemplifies excellence in research and development, focusing on the creation of unique therapies that cater to rare and complex diseases.

A Swiss-registered pharmaceutical wholesaler holds a valuable Good Distribution Practice (GDP) authorization from Swissmedic. The company possesses comprehensive wholesale licensing for pharmaceutical products, enabling both national and international trade operations, including import, export, and raw materials wholesale activities. Operating with a small team from its Winterthur location, the business is structured to serve the global pharmaceutical market.

Strategic Value Proposition
The primary asset of the company is its GDP license, which acts as a significant barrier to entry in the pharmaceutical wholesale sector. Total investment to date amounts to CHF 230,566.18, covering complete operational setup and regulatory compliance. The business offers flexibility in acquisition structure, with options for a financed complete purchase.

Swiss Pharmaceutical Industry & Tax Advantages
Switzerland’s pharmaceutical sector is a premier global hub, home to industry leaders and renowned for its quality and regulatory excellence. A licensed operation benefits from this prestigious ecosystem, where pharmaceutical products command premium pricing and enjoy streamlined access to both EU and global markets. The Swiss regulatory framework, while stringent, offers significant advantages through mutual recognition agreements with major markets, facilitating international trade operations.

From a tax perspective, Switzerland provides compelling advantages for pharmaceutical operations. The country’s corporate tax rates are among Europe’s most competitive, typically ranging from 11.9% to 21.6%, depending on the canton. Switzerland’s patent box regime allows for preferential taxation of patent-related income, with up to 90% tax relief on qualifying income. Additionally, companies can benefit from R&D super-deductions and tax-efficient handling of intellectual property rights. The stability and transparency of the Swiss tax system, combined with an extensive network of double taxation treaties, create an optimal environment for international pharmaceutical trade and investment.

The GDP authorization’s scope covers comprehensive pharmaceutical wholesale operations, positioning the acquirer for immediate market entry into the regulated pharmaceutical distribution sector. While currently pre-revenue, the established regulatory framework and operational infrastructure provide a turnkey solution for entering the Swiss and international pharmaceutical wholesale market.

Keypoints

Registration Address: Winterthur, Swiss
Type of Entity: GmbH
Banking Relationship: Zürcher Kantonal Bank
Regulatory Licence: Swissmedic GDP